24 August 2020>: Lab/In Vitro Research
Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells
Jiansheng Zhong 1ABE* , Jinli Zhang 2AB , Xiaoyang Yu 3BF , Xing Zhang 1CD , Linping Dian 1CDDOI: 10.12659/MSM.924922
Med Sci Monit 2020; 26:e924922
Figure 5 Olmutinib potentiated the efficacy of Dox in ETS1-overexpressing leukemia cell xenograft model in vivo. (A–C) The image of tumor size excised from the mice and the euthanized mice after implantation in different groups. (D–F) The alteration of tumor volume (D), tumor diameter (E) and body weight (F) over time after K562/ADR ETS1 overexpressing cells implantation, in mice received saline, Dox, Olm or Olm+Dox, respectively. (n=3). * P<0.05, ** P<0.01 and *** P<0.001 vs. Saline; # P<0.05, ## P<0.01 and ### P<0.001 vs. Olm; & P<0.05, && P<0.01 and &&& P<0.001 vs. Dox. (G) Mean tumor weight after excising from the mice on the 30th day after implantation (n=3). ** P<0.01 vs. Saline. Dox – doxorubicin; Olm – olmutinib.